WJP VICOM Ltd
- 1.360
- 0.0000.00%
VICOM Ltd News
Investors in VICOM (SGX:WJP) Have Unfortunately Lost 27% Over the Last Three Years
Vicom Ltd Holds Successful Hybrid 43rd AGM
Here's Why We're Wary Of Buying VICOM's (SGX:WJP) For Its Upcoming Dividend
Dajia Weikang (301126.SZ) announced first-quarter results, net profit of 19.436,900 yuan, an increase of 27.14%
Dajia Weikang (301126.SZ) released its report for the first quarter of 2024, achieving 12 operating income during the reporting period...
Shareholders May Be More Conservative With VICOM Ltd's (SGX:WJP) CEO Compensation For Now
Vicom Ltd Prepares for Hybrid 43rd AGM
VICOM Ltd's (SGX:WJP) Top Owners Are Public Companies With 67% Stake, While 27% Is Held by Individual Investors
Dajia Weikang (301126.SZ) plans to spend 10 million yuan to 15 million yuan to implement a repurchase
Dajia Weikang (301126.SZ) announced that the company plans to use its own funds to repurchase the company department through centralized bidding transactions...
VICOM (SGX:WJP) Is Due To Pay A Dividend Of SGD0.0275
A Look At The Intrinsic Value Of VICOM Ltd (SGX:WJP)
Dajia Weikang (301126.SZ), a specific shareholder, Liangji Investment, and the concerted actor Chunkang Investment reduced their holdings by 2.905 million shares
Dajia Weikang (301126.SZ) announced that the company's specific shareholder, Ningbo Meishan Bonded Port Area Liangji Equity Investment Partnership...
Weikang Pharmaceutical (300878.SZ): A total cost of 49.998 million yuan to buy back 1.89% of the shares
Gelonghui, Feb. 27丨Weikang Pharmaceutical (300878.SZ) announced that as of the disclosure date of this announcement, the company had repurchased 2,739,026 shares through a dedicated repurchase account, accounting for 1.89% of the company's total share capital. The highest transaction price was 20.08 yuan/share, the minimum transaction price was 16.66 yuan/share, and the total transaction amount was 49,998,352 yuan. The company's current repurchase plan has been implemented. The actual time period for share repurchase is from February 19, 2024 to February 26, 2024.
VICOM (SGX:WJP) Has Announced A Dividend Of SGD0.0275
Vicom's H2 Net Profit Climbs 4.5% to S$13.7 Million on Higher Revenue
VEHICLE inspection company Vicom reported on Wednesday (Feb 21) a 4.5 per cent increase in net profit for the second half of 2023, on the back of higher revenue.
Weikang Pharmaceutical (300878.SZ): A total cost of 347.277 million yuan to buy back 1.35% of shares
Gelonghui, Feb. 21丨Weikang Pharmaceutical (300878.SZ) announced that as of February 20, 2024, the company had repurchased a total of 1,955,626 shares through the Shenzhen Stock Exchange stock trading system, accounting for 1.35% of the company's current total share capital. The highest transaction price for the repurchase was 18.43 yuan/share, the minimum transaction price was 16.66 yuan/share, and the total transaction amount was RMB 34,727,682.
Weikang Pharmaceutical (300878.SZ): Initial repurchase of 391,200 shares involving 6.658 million yuan
Gelonghui, Feb. 20, 丨 Weikang Pharmaceutical (300878.SZ) announced that on February 19, 2024, the company repurchased 3911.73 million shares for the first time through the Shenzhen Stock Exchange stock trading system, accounting for 0.27% of the company's current total share capital. The highest transaction price for the repurchase was 1707 yuan/share, the minimum transaction price was 16.88 yuan/share, and the total transaction amount was RMB 66507.97 million (excluding transaction fees).
Weikang Pharmaceutical (300878.SZ) plans to spend 25 million yuan to 50 million yuan to buy back shares
Weikang Pharmaceutical (300878.SZ) issued an announcement that the company plans to use its own funds to buy back the public through centralized bidding transactions...
Weikang Pharmaceutical (300878.SZ) terminated the issuance of convertible bonds
Weikang Pharmaceutical (300878.SZ) issued an announcement. The company held the third board meeting on February 7, 2024...
Dajia Weikang (30112.SZ) grants 1.26 million Class II restricted shares and 2.94 million stock options
Zhitong Finance App News, Dajia Weikang (301126.SZ) announced that the grant conditions stipulated in the “Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. 2023 Restricted Stock and Stock Option Incentive Plan (Draft)” have been fulfilled. The company determined that January 22, 2024 is the first grant date for Class II restricted shares and the first authorization date for stock options, to grant 1.26 million Class II restricted shares and 2.94 million stock options to 33 eligible incentive recipients; the grant price is 6.88 yuan/share, and the exercise price is 13.76 yuan/share.
Dajia Weikang (301126.SZ): Currently actively applying for the qualification of a tertiary specialist hospital
Gelonghui, January 11丨Dajia Weikang (301126.SZ) said on the investor interactive platform that the company is currently actively applying for the qualification of a tertiary specialist hospital, the barriers to assisted reproductive technology are high, and the license application process is long. In the future, the company will fulfill its information disclosure obligations in strict accordance with the requirements of relevant laws and regulations. Stock price fluctuations in the secondary market are affected by multiple factors such as macroeconomics, policy environment, market fluctuations, and investor preferences. The company continuously strives to operate well, consolidate the foundation, and enhance the company's internal investment value. If there is a relevant share repurchase plan in the future, the company will strictly comply with the requirements of relevant laws and regulations to fulfill the information disclosure requirements
Analysis
Price Target
No Data
